Matrix Metalloproteinase 9 Gene Promoter (rs 3918242) Mutation Reduces the Risk of Diabetic Microvascular Complications

Int J Environ Res Public Health. 2015 Jul 14;12(7):8023-33. doi: 10.3390/ijerph120708023.

Abstract

Background: Many studies have evaluated the association between matrix metalloproteinase 9 (MMP9) gene promoter polymorphism and diabetic microvascular complications. However, the results are conflicting and inconclusive. The aim of this meta-analysis was to evaluate the association more precisely.

Materials and methods: Studies were retrieved from the PubMed, Embase, Medline, China National Knowledge Infrastructure, Web of Science, and Cochrane databases. All statistical analyses were performed using Review Manager 5.2.

Results: Data were abstracted from four case-control studies that included 446 patients with diabetic microvascular complications and 496 diabetic control subjects. The MMP9-1562 C/T genotype was significantly associated with the risk of diabetic nephropathy after stratification by specific type of microvascular complication (CT + TT vs. CC: OR = 0.42, 95% CI = 0.26-0.69, p = 0.0006; TT vs. CC + CT: OR = 0.37, 95% CI = 0.19-0.76, p = 0.006).

Conclusions: This study adds to the evidence that MMP9-1562 T gene mutation might reduce the risk of diabetic nephropathy.

Keywords: diabetes mellitus; matrix metalloproteinase 9; meta-analysis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Case-Control Studies
  • China
  • Diabetic Angiopathies / prevention & control*
  • Female
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Male
  • Matrix Metalloproteinase 9 / genetics*
  • Middle Aged
  • Mutation
  • Polymorphism, Genetic*
  • Promoter Regions, Genetic*
  • Risk

Substances

  • Matrix Metalloproteinase 9